Background Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct‐acting antivirals …
Y Xu, L Li, Y Yang, C Huang, H Zou - Talanta, 2024 - Elsevier
Developing a simple, reliable, and sensitive hepatitis C virus (HCV) genetic sensing platform is of great significance for diagnosing diseases and selecting appropriate antiviral …
Direct-acting antivirals (DAAs) revolutionized therapeutics of chronic hepatitis C. The emergence and transmission of HCV variants with resistance-associated substitutions …
Hepatitis C virus (HCV) remains a significant global health challenge. Approximately 50 million people were living with chronic hepatitis C based on the World Health Organization …
G Morsica, R Vercesi, H Hasson, E Messina… - Viruses, 2021 - mdpi.com
Resistance-associated substitutions (RASs) may exist prior to treatment and contribute to the failure of treatment with direct-acting antivirals (DAAs). As the major site of HCV replication …
Abstract Hepatitis C Virus (HCV) induces liver inflammation, which can develop to liver cirrhosis and hepatocellular carcinoma. In 2021, approximately 58 million people are …